YTHDC1 and glioblastoma: RBM15, METTL3, METTL14, ALKBH5, FTO, YTHDC1, and YTHDF2 are significantly differentially expressed between IDH-mutant and IDH-wildtype LGG. METTL3, FTO, and YTHDC1 are significantly differentially expressed between IDH-mutant and IDH-wildtype GBM. The risk signature comprises RBM15, WTAP, ALBKH5, FTO, YTHDC1, YTHDF1, and YTHDF2, all of which are independent prognostic markers and predictive of clinicopathological features and treatment sensitivity.